{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical information and guidelines, including those related to Cushing's syndrome.)\n##\n(\"entity\"<|>NIEMAN LK<|>PERSON<|>Nieman LK is a medical professional who has authored multiple reviews and guidelines on Cushing's syndrome.)\n##\n(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol, with various clinical manifestations and treatment guidelines.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is a professional organization that provides clinical practice guidelines for the diagnosis and treatment of endocrine disorders, including Cushing's syndrome.)\n##\n(\"entity\"<|>HYPERALDOSTERONISM<|>EVENT<|>Hyperaldosteronism is a condition characterized by excessive secretion of aldosterone, which can lead to hypertension and other health issues.)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>EVENT<|>Glucocorticoids are a class of steroid hormones that can be used in the treatment of conditions like hyperaldosteronism.)\n##\n(\"relationship\"<|>NIEMAN LK<|>UPTODATE INC.<|>Nieman LK has authored multiple articles and guidelines published by UpToDate Inc. regarding Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>UPTODATE INC.<|>CUSHING'S SYNDROME<|>UpToDate Inc. provides comprehensive information and guidelines on Cushing's syndrome<|>7)\n##\n(\"relationship\"<|>ENDOCRINE SOCIETY<|>CUSHING'S SYNDROME<|>The Endocrine Society issues clinical practice guidelines for the diagnosis and treatment of Cushing's syndrome<|>7)\n##\n(\"relationship\"<|>NIEMAN LK<|>ENDOCRINE SOCIETY<|>Nieman LK has contributed to the Endocrine Society's guidelines on Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>HYPERALDOSTERONISM<|>CUSHING'S SYNDROME<|>Hyperaldosteronism can be a condition that is differentiated from Cushing's syndrome in clinical practice<|>4)\n##\n(\"relationship\"<|>GLUCOCORTICOIDS<|>HYPERALDOSTERONISM<|>Glucocorticoids are used in the treatment of hyperaldosteronism, particularly in familial cases<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ushing. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es (última modificación: 25 de noviembre de 2015).\n- Nieman LK. Epidemiology and clinical manifestations of Cushing's syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Literature review current through: Apr. 2019.\n- Nieman LK. Establishing the diagnosis of Cushing's syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Literature review current through: Apr. 2019.\n- Nieman LK. Overview of the treatment of Cushing's syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Literature review current through: Apr. 2019.\n- Nieman LK, Biller BMK, Findiling JW, Murad MH, Newel-Price J, Savage MO, et al. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31.\n- Nieman LK, Biller BMK, Findiling JW, Newel-Price J, Savage MO, Steward PM, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-40.\n- Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 490-555.\n\n## 5.3 Hiperaldosteronismo\n\n## 15 El hiperaldosteronismo familiar remediable con corticoides es el de:\n\nA. Tipo 1.\nB. Tipo 2.\nC. Tipo 3.\nD. Tipo 4.\n---\nSUPRARRENALES 5\n\n## COMENTARIO\n\nEl hiperaldosteronismo primario se produce por un exceso de secreción autónoma de aldosterona por la glándula suprarrenal. Según las últimas series, su prevalencia es superior al 5-10% entre los pacientes con hipertensión arterial.\n\nEl hiperaldosteronismo primario puede deberse a:\n\n- Adenoma suprarrenal productor de aldosterona (enfermedad de Conn).\n- Hiperaldosteronismo idiopático por hiperplasia unilateral o bilateral.\n- Hiperaldosteronismo familiar.\n- Carcinoma suprarrenal productor de aldosterona.\n\nEl hiperaldosteronismo familiar de tipo 1 o hiperaldosteronismo familiar remediable con glucocorticoides es un síndrome hereditario autosómico dominante, responsable del 1% de todos los casos de hiperaldosteronismo primario.\n\nEn este caso, la enfermedad se debe a la presencia de un gen quimérico resultado del entrecruzamiento de las secuencias promotoras entre los genes CYP11B1 y CYP11B2 que participan en la biosíntesis de glucocorticoides y mineralocorticoides, respectivamente. Este reordenamiento hace que la transcripción de CYP11B2 se encuentre bajo el control de la señalización del receptor de ACTH; por ello, la producción de aldosterona pasa a estar regulada por la ACTH más que por la renina.\n\nSu presentación clínica es muy variable, con pacientes que presentan valores de presión arterial dentro de la normalidad y pacientes que presentan un cuadro clínico típico de hiperaldosteronismo primario con hipertensión arterial grave, resistente al tratamiento y de inicio a una edad temprana. Los antecedentes familiares pueden ser de gran utilidad y el riesgo será muy alto en caso de identificar a pacientes con hipertensión grave o resistente desde la infancia o la juventud que además tienen una historia familiar de hipertensión desde una edad temprana o enfermedad vascular cerebral hemorrágica prematura.\n\nSu identificación es importante porque puede estar asociada con hipertensión de inicio temprano y con enfermedad vascular cerebral. Además, el tratamiento con glucocorticoides a dosis bajas puede reducir la producción de aldosterona y controlar la enfermedad.\n\nPara su diagnóstico se recomienda el estudio genético directo, que debería reemplazar a las pruebas clásicas indirectas como el test de supresión con dexametasona. El estudio genético de hiperaldosteronismo familiar tipo 1 debería considerarse en todos los pacientes con hiperaldosteronismo primario que presentan historia familiar de hiperaldosteronismo primario o ictus a una edad joven y en pacientes con hiperaldosteronismo primario menores de 20 años.\n\nEl hiperaldosteronismo familiar de tipo 2 es un trastorno con comportamiento autosómico dominante, pero en el que no existe supresión de la aldosterona con dexametasona ni un resultado positivo en el estudio genético. Los pacientes son indistinguibles del resto de pacientes con hiperaldosteronismo primario y pueden presentar una enfermedad unilateral o bilateral. Aunque no se conoce exactamente la base molecular de esta enfermedad, los estudios de asociación familiar la han relacion\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}